Clinical Trials Browser

Phase 2 × Glioma × Protein Subunit Vaccines × Clear all

NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

Glioblastoma, Glioma